6ML0 Stock Overview
A clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Molecular Partners AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 5.60 |
| 52 Week High | CHF 5.60 |
| 52 Week Low | CHF 3.16 |
| Beta | 0.54 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 40.00% |
| 3 Year Change | -39.13% |
| 5 Year Change | n/a |
| Change since IPO | -65.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6ML0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 3.1% | 0.5% |
| 1Y | 40.0% | -13.8% | 7.2% |
Return vs Industry: 6ML0 exceeded the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: 6ML0 exceeded the German Market which returned 8.3% over the past year.
Price Volatility
| 6ML0 volatility | |
|---|---|
| 6ML0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6ML0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 6ML0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 162 | Patrick Amstutz | www.molecularpartners.com |
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors.
Molecular Partners AG Fundamentals Summary
| 6ML0 fundamental statistics | |
|---|---|
| Market cap | €191.39m |
| Earnings (TTM) | -€66.93m |
| Revenue (TTM) | €6.42m |
29.8x
P/S Ratio-2.9x
P/E RatioIs 6ML0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6ML0 income statement (TTM) | |
|---|---|
| Revenue | CHF 6.00m |
| Cost of Revenue | CHF 49.97m |
| Gross Profit | -CHF 43.96m |
| Other Expenses | CHF 18.63m |
| Earnings | -CHF 62.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.70 |
| Gross Margin | -732.47% |
| Net Profit Margin | -1,042.84% |
| Debt/Equity Ratio | 0% |
How did 6ML0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/11/17 13:43 |
| End of Day Share Price | 2024/08/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Molecular Partners AG is covered by 14 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Maurizio Bernasconi | Bank am Bellevue |
| null null | Credit Suisse |
| Thomas Kaufmann | Credit Suisse |